Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (42750)	3/21/2002 3:13:12 PM
From: Sully-	Respond to of 99280

15:02 ET Pfizer reaffirms 2002-04 guidance (PFE) 39.67 -0.41: Co confirms its previous guidance for 2002-04 as discussed in its Jan 23 earning press release; for 2002, the co is comfortable with double-digit rev growth and EPS in the range of $1.56-$1.60 (consensus is $1.59), and the co continues to target double-digit rev growth and EPS growth of 15% or better for 2003-04. 15:04 ET Teva Pharm announces resolution of Fenofibrate litigation (TEVA) 56.09 -0.48: Announces that a U.S. District Court has granted Summary Judgement of Non-infringement regarding Teva's ANDA for Fenofibrate capsules. The court decision will allow the FDA approve Teva's ANDA for this product which seeks AB-rating to Abbott's Tricor capsules.